Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 16, 2022

Postoperative Adverse Events in Treatment-Naïve Patients With Oral Cavity SCC Receiving Neoadjuvant Pembrolizumab

JAMA Otolaryngology -- Head & Neck Surgery


Additional Info

JAMA Otolaryngology -- Head & Neck Surgery
Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients
JAMA Otolaryngol Head Neck Surg 2022 Aug 25;[EPub Ahead of Print], AL Tang, T O'Neil, S McDermott, S Tripathi, R Tikhtman, JR Mark, Y Patil, M Tabangin, M Altaye, TM Wise-Draper, CA Zender

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading